Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Status:
Recruiting
Trial end date:
2027-06-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical
benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed
multiple myeloma who are MRD-positive after undergoing autologous stem cell transplant.
Participants in the study will either receive elrantamab as an injection under the skin at
the study clinic or lenalidomide orally once daily at home. Participants who will receive
elranatamab will start receiving one dose every week after the initial step-up doses. After 6
months of treatment, the frequency of clinic visits for injections will decrease to every
other week. Participation in the study will be approximately five years.